An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership

Axsome’s CRL was not the first from the US FDA for the nearly insoluble NSAID as sponsors try different technologies for delivering its pain relief quickly.

Lupin will be able to launch a deutetrabenazine generic rival to Teva’s Austedo brand in the US from 2033, following a settlement agreement between the two firms. However, Aurobindo is continuing to fight a patent-infringement suit with the Israeli firm.